Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer

Abstract

Tumors are cellularly and molecularly heterogeneous, with subsets of undifferentiated cancer cells exhibiting stem cell-like features (CSCs). Epithelial to mesenchymal transitions (EMT) are transdifferentiation programs that are required for tissue morphogenesis during embryonic development. The EMT process can be regulated by a diverse array of cytokines and growth factors, such as transforming growth factor (TGF)-β, whose activities are dysregulated during malignant tumor progression. Thus, EMT induction in cancer cells results in the acquisition of invasive and metastatic properties. Recent reports indicate that the emergence of CSCs occurs in part as a result of EMT, for example, through cues from tumor stromal components. Recent evidence now indicates that EMT of tumor cells not only causes increased metastasis, but also contributes to drug resistance. In this review, we will provide potential mechanistic explanations for the association between EMT induction and the emergence of CSCs. We will also highlight recent studies implicating the function of TGF-β-regulated noncoding RNAs in driving EMT and promoting CSC self-renewal. Finally we will discuss how EMT and CSCs may contribute to drug resistance, as well as therapeutic strategies to overcome this clinically.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4

References

  • Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF . (2003). Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100: 3983–3988.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ashburner BP, Westerheide SD, Baldwin Jr S . (2001). The p65 (RelA) subunit of NF-kappaB interacts with the histone deacetylase (HDAC) corepressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 21: 7065–7077.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Banito A, Rashid ST, Acosta JC, Li S, Pereira CF, Geti I et al. (2009). Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev 23: 2134–2139.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al. (2009). SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238–1242.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Baulcombe DC . (2006). Short silencing RNA: the dark matter of genetics? Cold Spring Harb Symp Quant Biol 71: 13–20.

    CAS  PubMed  Google Scholar 

  • Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499–507.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Bonnet D, Dick JE . (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730–737.

    Article  CAS  PubMed  Google Scholar 

  • Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S et al. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep 9: 582–589.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al. (2007). The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329–2334.

    CAS  PubMed  Google Scholar 

  • Chng Z, Teo A, Pedersen RA, Vallier L . (2010). SIP1 mediates cell-fate decisions between neuroectoderm and mesendoderm in human pluripotent stem cells. Cell Stem Cell 6: 59–70.

    CAS  PubMed  Google Scholar 

  • Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E et al. (2001). The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell 7: 1267–1278.

    CAS  PubMed  Google Scholar 

  • Conery AR, Cao Y, Thompson EA, Townsend Jr M, Ko TC, Luo K . (2004). Akt interacts directly with Smad3 to regulate the sensitivity to TGF-beta induced apoptosis. Nat Cell Biol 6: 366–372.

    CAS  PubMed  Google Scholar 

  • Davis BN, Hilyard AC, Lagna G, Hata A . (2008). SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454: 56–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Deonarain MP, Kousparou CA, Epenetos AA . (2009). Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 1: 12–25.

    PubMed  PubMed Central  Google Scholar 

  • Derynck R, Akhurst RJ, Balmain A . (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117–129.

    CAS  PubMed  Google Scholar 

  • Dubrovska A, Kim S, Salamone RJ, Walker JR, Maira SM, Garcia-Echeverria C et al. (2009). The role of PTEN/Akt/PI3 K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106: 268–273.

    CAS  PubMed  Google Scholar 

  • Dvorak HF . (1986). Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315: 1650–1659.

    CAS  PubMed  Google Scholar 

  • Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. (2007). MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316: 1039–1043.

    Article  CAS  PubMed  Google Scholar 

  • Feuring-Buske M, Hogge DE . (2001). Hoechst 33342 efflux identifies a subpopulation of cytogenetically normal CD34(+)CD38(−) progenitor cells from patients with acute myeloid leukemia. Blood 97: 3882–3889.

    CAS  PubMed  Google Scholar 

  • Gal A, Sjoblom T, Fedorova L, Imreh S, Beug H, Moustakas A . (2008). Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 27: 1218–1230.

    CAS  PubMed  Google Scholar 

  • Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ et al. (2009). Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev 23: 2140–2151.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M et al. (2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1: 555–567.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G et al. (2008). The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10: 593–601.

    CAS  PubMed  Google Scholar 

  • Gupta PB, Chaffer CL, Weinberg RA . (2009a). Cancer stem cells: mirage or reality? Nat Med 15: 1010–1012.

    CAS  PubMed  Google Scholar 

  • Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA et al. (2009b). Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645–659.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC . (2008). PI3 K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22: 436–448.

    CAS  PubMed  PubMed Central  Google Scholar 

  • He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. (2005). A microRNA polycistron as a potential human oncogene. Nature 435: 828–833.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Heldin CH, Landstrom M, Moustakas A . (2009). Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition. Curr Opin Cell Biol 21: 166–176.

    CAS  PubMed  Google Scholar 

  • Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M et al. (2007). Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313–323.

    CAS  PubMed  Google Scholar 

  • Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K . (2009). Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69: 7507–7511.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Huber MA, Kraut N, Beug H . (2005). Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548–558.

    CAS  PubMed  Google Scholar 

  • Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH et al. (2002). Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111: 709–720.

    CAS  PubMed  Google Scholar 

  • Kato M, Putta S, Wang M, Yuan H, Lanting L, Nair I et al. (2009). TGF-beta activates Akt kinase through a microRNA-dependent amplifying circuit targeting PTEN. Nat Cell Biol 11: 881–889.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Keniry M, Parsons R . (2008). The role of PTEN signaling perturbations in cancer and in targeted therapy. Oncogene 27: 5477–5485.

    CAS  PubMed  Google Scholar 

  • Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS et al. (2008). MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol 28: 6773–6784.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J . (2006). Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol 26: 2019–2028.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Korpal M, Lee ES, Hu G, Kang Y . (2008). The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283: 14910–14914.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell 137: 1005–1017.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J et al. (2006). Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 442: 818–822.

    CAS  PubMed  Google Scholar 

  • Kuhnle M, Egger M, Muller C, Mahringer A, Bernhardt G, Fricker G et al. (2009). Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. J Med Chem 52: 1190–1197.

    PubMed  Google Scholar 

  • LaGamba D, Nawshad A, Hay ED . (2005). Microarray analysis of gene expression during epithelial-mesenchymal transformation. Dev Dyn 234: 132–142.

    CAS  PubMed  Google Scholar 

  • Lane AA, Chabner BA . (2009). Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459–5468.

    CAS  PubMed  Google Scholar 

  • Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645–648.

    CAS  PubMed  Google Scholar 

  • Leder A, Orkin S, Leder P . (1975). Differentiation of erythroleukemic cells in the presence of inhibitors of DNA synthesis. Science 190: 893–894.

    CAS  PubMed  Google Scholar 

  • Li H, Collado M, Villasante A, Strati K, Ortega S, Canamero M et al. (2009a). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460: 1136–1139.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. (2008). Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 100: 672–679.

    CAS  PubMed  Google Scholar 

  • Li Y, VandenBoom II TG, Kong D, Wang Z, Ali S, Philip PA et al. (2009b). Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704–6712.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al. (2008). Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275–1281.

    PubMed  Google Scholar 

  • Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH et al. (2009). Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 15: 907–913.

    CAS  PubMed  Google Scholar 

  • Liu Y, Clem B, Zuba-Surma EK, El-Naggar S, Telang S, Jenson AB et al. (2009). Mouse fibroblasts lacking RB1 function form spheres and undergo reprogramming to a cancer stem cell phenotype. Cell Stem Cell 4: 336–347.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL . (2007). Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev Biol 310: 442–453.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Malanchi I, Peinado H, Kassen D, Hussenet T, Metzger D, Chambon P et al. (2008). Cutaneous cancer stem cell maintenance is dependent on beta-catenin signalling. Nature 452: 650–653.

    CAS  PubMed  Google Scholar 

  • Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133: 704–715.

    CAS  PubMed  PubMed Central  Google Scholar 

  • McCaughan F, Pole JC, Bankier AT, Konfortov BA, Carroll B, Falzon M et al. (2010). Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer. Am J Respir Crit Care Med (e-pub ahead of print 18 March 2010).

  • Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127.

    CAS  PubMed  Google Scholar 

  • Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515–527.

    CAS  PubMed  PubMed Central  Google Scholar 

  • O'Brien CA, Pollett A, Gallinger S, Dick JE . (2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106–110.

    CAS  PubMed  Google Scholar 

  • Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. (2006). Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24: 3726–3734.

    CAS  PubMed  Google Scholar 

  • Pardal R, Clarke MF, Morrison SJ . (2003). Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895–902.

    CAS  PubMed  Google Scholar 

  • Park SM, Gaur AB, Lengyel E, Peter ME . (2008). The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22: 894–907.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Peacock CD, Watkins DN . (2008). Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 26: 2883–2889.

    CAS  PubMed  Google Scholar 

  • Peinado H, Olmeda D, Cano A . (2007). Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7: 415–428.

    CAS  PubMed  Google Scholar 

  • Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I et al. (2008). E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13: 272–286.

    CAS  PubMed  Google Scholar 

  • Polyak K, Weinberg RA . (2009). Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265–273.

    CAS  PubMed  Google Scholar 

  • Postigo AA, Depp JL, Taylor JJ, Kroll KL . (2003). Regulation of Smad signaling through a differential recruitment of coactivators and corepressors by ZEB proteins. EMBO J 22: 2453–2462.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ . (2008). Efficient tumour formation by single human melanoma cells. Nature 456: 593–598.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE et al. (2000). The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901–906.

    CAS  PubMed  Google Scholar 

  • Remy I, Montmarquette A, Michnick SW . (2004). PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Nat Cell Biol 6: 358–365.

    CAS  PubMed  Google Scholar 

  • Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111–115.

    CAS  PubMed  Google Scholar 

  • Riggs MG, Whittaker RG, Neumann JR, Ingram VM . (1977). n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268: 462–464.

    CAS  PubMed  Google Scholar 

  • Robey RW, Shukla S, Steadman K, Obrzut T, Finley EM, Ambudkar SV et al. (2007). Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure. Mol Cancer Ther 6: 1877–1885.

    CAS  PubMed  Google Scholar 

  • Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR et al. (2009). Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 69: 2887–2895.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Sayan AE, Griffiths TR, Pal R, Browne GJ, Ruddick A, Yagci T et al. (2009). SIP1 protein protects cells from DNA damage-induced apoptosis and has independent prognostic value in bladder cancer. Proc Natl Acad Sci USA 106: 14884–14889.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Seoane J, Le HV, Shen L, Anderson SA, Massague J . (2004). Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117: 211–223.

    CAS  PubMed  Google Scholar 

  • Sharma SV, Bell DW, Settleman J, Haber DA . (2007). Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169–181.

    CAS  PubMed  Google Scholar 

  • Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S et al. (2010). A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J et al. (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259–273.

    CAS  PubMed  Google Scholar 

  • Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N et al. (2009). A gene expression signature associated with ‘K-Ras addiction’ reveals regulators of EMT and tumor cell survival. Cancer Cell 15: 489–500.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396–401.

    CAS  PubMed  Google Scholar 

  • Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Takahashi K, Yamanaka S . (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126: 663–676.

    CAS  PubMed  Google Scholar 

  • Thiery JP . (2003). Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15: 740–746.

    CAS  PubMed  Google Scholar 

  • Thiery JP, Acloque H, Huang RY, Nieto MA . (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139: 871–890.

    CAS  PubMed  Google Scholar 

  • Thuault S, Valcourt U, Petersen M, Manfioletti G, Heldin CH, Moustakas A . (2006). Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol 174: 175–183.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Utikal J, Polo JM, Stadtfeld M, Maherali N, Kulalert W, Walsh RM et al. (2009). Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460: 1145–1148.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Verschueren K, Remacle JE, Collart C, Kraft H, Baker BS, Tylzanowski P et al. (1999). SIP1, a novel zinc finger/homeodomain repressor, interacts with Smad proteins and binds to 5′-CACCT sequences in candidate target genes. J Biol Chem 274: 20489–20498.

    CAS  PubMed  Google Scholar 

  • Voulgari A, Pintzas A . (2009). Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim Biophys Acta 1796: 75–90.

    CAS  PubMed  Google Scholar 

  • Wang SE, Xiang B, Guix M, Olivares MG, Parker J, Chung CH et al. (2008). Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol 28: 5605–5620.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A et al. (2009). The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 11: 1487–1495.

    CAS  PubMed  Google Scholar 

  • Wendt MK, Allington TM, Schiemann WP . (2009). Mechanisms of the epithelial-mesenchymal transition by TGF-beta. Future Oncol 5: 1145–1168.

    CAS  PubMed  Google Scholar 

  • Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R et al. (1999). Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J Pathol 154: 515–523.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L et al. (2006). Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66: 944–950.

    CAS  PubMed  Google Scholar 

  • Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY et al. (2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 136: 1012–1024.

    CAS  PubMed  Google Scholar 

  • Yang J, Weinberg RA . (2008). Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818–829.

    CAS  PubMed  Google Scholar 

  • Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L et al. (2005). Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686–8698.

    CAS  PubMed  Google Scholar 

  • Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475–482.

    CAS  PubMed  Google Scholar 

  • Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. (2007a). let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131: 1109–1123.

    CAS  PubMed  Google Scholar 

  • Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S et al. (2007b). Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917–1920.

    CAS  PubMed  Google Scholar 

  • Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM et al. (2010). Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5: e9112.

    PubMed  PubMed Central  Google Scholar 

  • Zeisberg M, Neilson EG . (2009). Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429–1437.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB . (2009). Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 8: 806–823.

    CAS  PubMed  Google Scholar 

  • Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J et al. (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104: 16158–16163.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J Settleman.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Singh, A., Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741–4751 (2010). https://doi.org/10.1038/onc.2010.215

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2010.215

Keywords

  • EMT
  • cancer
  • cancer stem cells
  • drug resistance

This article is cited by

Search

Quick links